AbbVie Inks a Deal With Neomorph

Neomorph, AbbVie strike $1.64 billion deal
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see new data on a
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple targets across oncology and immunology.
AbbVie and Neomorph link on oncology/immunology glue degraders
AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology. Tailored to selectively target and induce the degradation of proteins associated with disease progression,
AbbVie To Collaborate With Neomorph To Develop Molecular Glue Degraders For Oncology And Immunology
AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular
AbbVie, Neomorph to develop molecular glue degraders
AbbVie (NYSE:ABBV) has entered into a collaboration agreement with Neomorph for the development of novel molecular glue degraders for multiple targets across oncology and immunology. Under the deal, Neomorph will receive an upfront payment and is eligible to receive up to $1.
AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...
Is AbbVie Stock a Buy?
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
William Blair Has Negative Outlook of AbbVie FY2024 Earnings
William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.
$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,026.90 today based on a ...
BioPharma Dive2d
Mixed results for Keytruda; AbbVie to work with Neomorph
Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...
Crain's Chicago Business11d
Despite $3.5B impairment charge on failed Cerevel drug, AbbVie still sees potential
The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...
AbbVie CEO says psychiatric drug space challenging, more cautious on investments
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
FiercePharma4d
AbbVie logs 3rd straight year as top TV drug ad spender
Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...
What is William Blair’s Forecast for AbbVie FY2025 Earnings?
Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...
AbbVie (ABBV) Receives a Buy from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...